+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Antifungal Drugs Market 2020-2024

  • PDF Icon

    Report

  • 120 Pages
  • November 2020
  • Region: Global
  • TechNavio
  • ID: 5205131
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Antifungal Drugs Market 2020-2024

The publisher has been monitoring the antifungal drugs market and it is poised to grow by USD 2.50 bn during 2020-2024 progressing at a CAGR of 4% during the forecast period. The reports on antifungal drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of fungal infections, emerging new targets for the treatment of resistant fungal infections and an increase in antifungal research funding. In addition, the increasing prevalence of fungal infections is anticipated to boost the growth of the market as well.

The antifungal drugs market analysis includes the route of administration segment and geographical landscapes.

The antifungal drugs market is segmented as below:

By Route of administration
  • Topical
  • Oral
  • Parenteral

By Geographical Landscapes
  • North America
  • Europe
  • Asia
  • ROW

This study identifies the use of antifungal combinations as one of the prime reasons driving the antifungal drugs market growth during the next few years. Also, use of immunomodulatory therapies for fungal infection and increasing awareness about fungal infections will lead to sizable demand in the market.

The antifungal drugs market covers the following areas:
  • Antifungal drugs market sizing
  • Antifungal drugs market forecast
  • Antifungal drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antifungal drugs market vendors that include Abbott Laboratories, Bayer AG, Eisai Co. Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., and Sanofi. Also, the antifungal drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Route of administration
  • Market segments
  • Comparison by Route of administration
  • Topical - Market size and forecast 2019-2024
  • Oral - Market size and forecast 2019-2024
  • Parenteral - Market size and forecast 2019-2024
  • Market opportunity by Route of administration

Customer Landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • Bayer AG
  • Eisai Co. Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2019 - 2024 ($ million)
  • Global market: Year-over-year growth 2019 - 2024 (%)
  • Five forces analysis 2019 & 2024
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2019
  • Other1 - Market share 2019-2024 (%)
  • Comparison by Other1
  • Topical - Market size and forecast 2019-2024 ($ million)
  • Topical - Year-over-year growth 2019-2024 (%)
  • Oral - Market size and forecast 2019-2024 ($ million)
  • Oral - Year-over-year growth 2019-2024 (%)
  • Parenteral - Market size and forecast 2019-2024 ($ million)
  • Parenteral - Year-over-year growth 2019-2024 (%)
  • Market opportunity by Other1
  • Customer landscape
  • Market share by geography 2019-2024 (%)
  • Geographic comparison
  • North America - Market size and forecast 2019-2024 ($ million)
  • North America - Year-over-year growth 2019-2024 (%)
  • Europe - Market size and forecast 2019-2024 ($ million)
  • Europe - Year-over-year growth 2019-2024 (%)
  • Asia - Market size and forecast 2019-2024 ($ million)
  • Asia - Year-over-year growth 2019-2024 (%)
  • ROW - Market size and forecast 2019-2024 ($ million)
  • ROW - Year-over-year growth 2019-2024 (%)
  • Key leading countries
  • Market opportunity by geography ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Key customers
  • Abbott Laboratories - Segment focus
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Key customers
  • Bayer AG - Segment focus
  • Eisai Co. Ltd. - Overview
  • Eisai Co. Ltd. - Business segments
  • Eisai Co. Ltd. - Key offerings
  • Eisai Co. Ltd. - Key customers
  • Eisai Co. Ltd. - Segment focus
  • Gilead Sciences Inc. - Overview
  • Gilead Sciences Inc. - Product and service
  • Gilead Sciences Inc. - Key offerings
  • Gilead Sciences Inc. - Key customers
  • Gilead Sciences Inc. - Segment focus
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Key customers
  • GlaxoSmithKline Plc - Segment focus
  • Glenmark Pharmaceuticals Ltd. - Overview
  • Glenmark Pharmaceuticals Ltd. - Product and service
  • Glenmark Pharmaceuticals Ltd. - Key offerings
  • Glenmark Pharmaceuticals Ltd. - Key customers
  • Glenmark Pharmaceuticals Ltd. - Segment focus
  • Johnson & Johnson - Overview
  • Johnson & Johnson - Business segments
  • Johnson & Johnson - Key offerings
  • Johnson & Johnson - Key customers
  • Johnson & Johnson - Segment focus
  • Merck & Co. Inc. - Overview
  • Merck & Co. Inc. - Business segments
  • Merck & Co. Inc. - Key offerings
  • Merck & Co. Inc. - Key customers
  • Merck & Co. Inc. - Segment focus
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Key customers
  • Pfizer Inc. - Segment focus
  • Sanofi - Overview
  • Sanofi - Business segments
  • Sanofi - Key offerings
  • Sanofi - Key customers
  • Sanofi - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global antifungal drugs market: Abbott Laboratories, Bayer AG, Eisai Co. Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., and Sanofi.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is use of antifungal combinations.'

According to the report, one of the major drivers for this market is the increasing prevalence of fungal infections.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Bayer AG
  • Eisai Co. Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi